3-[(4-Bromophenyl)methyl]-2-methoxyquinoline | 918648-52-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-[(4-Bromophenyl)methyl]-2-methoxyquinoline
• CAS: 918648-52-9
• 化学式: C₁₇H₁₄BrNO
• 分子量: 328.208
• InChiKey: KJXZJNGKLJOOOL-UHFFFAOYSA-N

物化性质

• 沸点：
  424.3±35.0 °C(Predicted)
• 密度：
  1.388±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-[(4-Bromophenyl)methyl]-2-methoxyquinoline 在 三甲基氯硅烷 、 (2-dicyclohexylphosphino-2’,6’-diisopropoxy-1,1‘-biphenyl)[2-(2’-methylamino-1,1’-biphenyl)]palladium(II) methanesulfonate 、 sodium iodide 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 36.0h， 生成 3-(4-(piperazin-1-yl)benzyl)quinolin-2(1H)-one
  参考文献：
  名称：

  [EN] IL4I1 INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS D'IL4I1 ET MÉTHODES D'UTILISATION

  摘要：

  Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof wherein A, E, U, X, Y, Z, R1, R2and n are as defined herein. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1 -related diseases. Also provided herein are pharmaceutical compositions comprising the compounds of the invention, or their pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier and methods of treatment with the compounds of the invention.

  公开号：

  WO2023278222A1
• 作为产物：
  描述：

  N-乙酰苯胺 在 甲醇 、 sodium tetrahydroborate 、 四(三苯基膦)钯 、 sodium carbonate 、 三苯基膦 、 potassium hydroxide 、 三氯氧磷 作用下， 以 四氢呋喃 、 四氯化碳 、 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， 反应 48.58h， 生成 3-[(4-Bromophenyl)methyl]-2-methoxyquinoline
  参考文献：
  名称：

  [EN] IL4I1 INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS D'IL4I1 ET MÉTHODES D'UTILISATION

  摘要：

  Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof wherein A, E, U, X, Y, Z, R1, R2and n are as defined herein. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1 -related diseases. Also provided herein are pharmaceutical compositions comprising the compounds of the invention, or their pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier and methods of treatment with the compounds of the invention.

  公开号：

  WO2023278222A1

文献信息

• WO2007/435
  申请人：——

  公开号：——

  公开（公告）日：——
• WO2008/68268
  申请人：——

  公开号：——

  公开（公告）日：——
• QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS
  申请人：Janssen Pharmaceutica NV

  公开号：EP1898914B1

  公开（公告）日：2012-08-15
• ANTIBACTERIAL QUINOLINE DERIVATIVES
  申请人：Guillemont Jérôme Emile Georges

  公开号：US20100029679A1

  公开（公告）日：2010-02-04

  The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or Formula (Ib): including any stereochemically isomeric form thereof, a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of a bacterial infection and a process for preparing the claimed compounds.
• US8293732B2
  申请人：——

  公开号：US8293732B2

  公开（公告）日：2012-10-23